CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907 · cited 1×
“perfusion injury (53)dconverge on insufficient mitochondrial energy output and contractile failure as the basic mechanism.”
BackgroundESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048 · cited 1×
“and functional manifestation (reduced or preserved ejection fraction) (51).”
Background
Cited by
Items 901–1,000 of 1,000
Yanagawa, T., Matsuda, H., Sugawara, M., Fukuda, M., & Sasaki, T. (2021) · Journal of Endocrinology and Metabolism · doi:10.14740/jem738
Galyautdinov, G. S., Zhidyaevskij, A. G., Nesterina, M. K., & Миннегалимова, К. Р. (2022) · The Bulletin of Contemporary Clinical Medicine · doi:10.20969/vskm.2022.15(2).89-94
“Таким образом, сердечная мышца начинает получать до-статочное количество кислорода в качестве «топли-ва» для синтеза необходимой энергии при окислении жирных кислот в отсутствие глюкозы [40,41].”
Patoulias, D., Papadopoulos, C. E., & Doumas, M. N. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.06.011
Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure
Mirzazada, V., kizi, S. S. S., Ismayilova, N., Huseynova, A., Nurmammadova, G., Ismayilova, S., & Aliyeva, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106391
SGLT-2 inhibitors: new effective drugs for treatment of heart failure
KRÓL, O., Gładysz, K., Szydłowska, J., ŻUCHNIK, O., Kwiatkowski, P., Czelej, M., KŁOS, A., GIEROBA, K., Szydłowski, M., & Zuchniak, P. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.02.007
Obesity in relation to cardiorenal function
Nguyen, I., Joles, J. A., Verhaar, M. C., Lamb, H. J., & Dekkers, I. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822186-0.00006-7
Overview about Correlation between Heart Failure and Diabetes Mellitus: Review Article
Mabrouk, A. R. R., Elmaghawry, L. M., Shereef, A. S., & El-Shetry, M. S. (2023) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2023.296743
Sodium-Glucose Cotransporter 2 Inhibitors
DAILEY, G. E., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_36
Effect of Sglt-2 Inhibitors on Renal Tubular Damage
Öztürk, O., Zengin, O., Deniz, M. S., Şahiner, E. S., İnan, O., Erel, Ö., & Ateş, İ. (2023) · Ankara City Hospital Medical Journal · doi:10.5505/achmedj.2023.39974
Principles of cardiovascular risk management in perimenopausal women with type 2 diabetes
Омариевна, У. Ф., Demidova, T. Y., & Korotkova, T. N. (2023) · FOCUS Endocrinology · doi:10.15829/1560-4071-2023-22
Ertürk, E., Ocak, K., Uyan, U., Çoner, A., Kocabaş, U., Kış, M., Başkurt, A. A., Oray, D., Sayın, B. Y., Mammadov, G., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2688
Chronic heart failure fosters the onset of type 2 diabetes mellitus
Márquez-Salom, G. A., Márquez-Zuccardi, Á., & Márquez-Fernández, A. (2023) · Revista Colombiana de Cardiología (English Edition) · doi:10.24875/rccare.m23000051
Cheng, C., Fan, Z., Ji, M., Xu, Y., He, S., & Ma, G. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12404 · Cited by 1
“The key patho‑ physiological factors contributing to HF progression include both the reduction in contractile units and the diminished mitochondrial bioenergetics within surviving cardiomyocytes after myocardial injuries (28,29).”
BackgroundIngason, A. B., & Norotsky, M. C. (2024) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000001085
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Figshare · doi:10.6084/m9.figshare.20438489
Dapaqliflozinin xroniki ürək çatışmazlığında tətbiqi
Baxşəliyeva, Q. İ. (2017) · doi:10.28942/acj.v24i2y2023.89
SGLT2 and GLP - 1 Inhibitors: Enlightening their Role beyond their Glucose Lowering Properties
Mehra, G. (2024) · International Journal of Science and Research (IJSR) · doi:10.21275/sr24408120904
“As a result, SGLT2 improves insulin resistance in diabetes by lowering the levels of glucose in an independent of insulin manner [39,40].”
Tessuto adiposo epicardico: dagli aspetti biomolecolari alla pratica clinica
Malavazos, A. E., Dubini, C., Meregalli, C., Boniardi, F., Secchi, F., Piepoli, M. F., Salvetti, G., Menicanti, L., Chessa, M., Spagnolo, P., et al. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01493-w · Cited by 1
“D’altra parte, nello scompenso cardiaco l’assorbimento di glucosio media-to dall’insulina e il suo metabolismo ossidativo mitocondria-394 le sono marcatamente compromessi [46].”
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_7
Sagara, R., Sonoda, N., Ikeda, M., Tohyama, T., Nishizaka, M., Yamasaki, Y., Tagawa, K., Hamase, K., Nakashima, N., Ishigami, K., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5351010/v1
de Wit‐Verheggen, V. H. W., Wefers, J., Remie, C. M. E., Schrauwen, P., Schrauwen‐Hinderling, V. B., & van de Weijer, T. (2025) · Physiological Reports · doi:10.14814/phy2.70242
“Furthermore, it has been noted, that the fluctuations of plasma FFA during the day, associated with food intake, are tightly associated with changes in the circulating levels of ketone bodies (Ferrannini et al., 2016, 2022).”
Царева, А. А., Разин, В. А., & Косинов, С. С. (2025) · Современные проблемы науки и образования · doi:10.17513/spno.33993
Intrinsic Ketogenic Capacity of the Heart: Mechanisms and Therapeutic Potential
Caputo, R., & Greco, C. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.326560
Росул, М. М., Блецкан, М. М., Ivanio, N. V., & Korabelschykova, M. O. (2025) · Науковий вісник Ужгородського університету Серія Медицина · doi:10.32782/2415-8127.2025.71.9
The Possible CardioprotectiveEffect of Empagliflozin During Endotoxemia in Mice Model
Al-killidar, S. M., & Muhammad-Baqir, B. M. (2025) · Maaen Journal for Medical Sciences · doi:10.55810/2789-9136.1074
Rastogi, S. K., Odeh, M. A., & Rastogi, P. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00002-6 · Cited by 1
Bae, J., Lee, M., Lee, Y., Lee, S., & Lee, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178566
Trefanenko, I. V., Shuper, V. О., & Hrechko, S. (2025) · Перспективи та інновації науки · doi:10.52058/2786-4952-2025-10(56)-2310-2323
Soni, A., Lawal, O. P., Oyovwi, J. O., Olaniyi, H. I., Anosike, W. O., Orobator, E. T., Gabriels, N., Ghori, I. A. K., & Olaniyi, A. O. (2025) · Cureus · doi:10.7759/cureus.96593
“…are consistent with the clinical guidelines from both the American Diabetes Association (ADA) and the European Society of Cardiology (ESC), which recommend the use of SGLT2 inhibitors in T2DM patients who either have established cardiovascular disease or are at elevated risk for heart failure [26].”
Metabolic health and intermittent fasting: implications for age-related disorders
Ghosh, S., Singh, K. K., Raghunath, M., & Sinha, J. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30060-8.00007-8 · Cited by 6
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010690
Chen, J., Jiang, C. Q., Guo, M., Zeng, Y., Jiang, Z., Zhang, D., Tu, M., Tan, X., 晏丕军, Xu, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24940601
Chen, J., Jiang, C. Q., Guo, M., Zeng, Y., Jiang, Z., Zhang, D., Tu, M., Tan, X., Yan, P., Xu, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24940964
Yu, Y.-W., Zhao, X.-M., Wang, Y.-H., Zhou, Q., Huang, Y., Zhai, M., & Zhang, J. (2021) · Figshare · doi:10.6084/m9.figshare.13642055
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010693
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferović, P. M., & Wanner, C. (2022) · Figshare · doi:10.6084/m9.figshare.20438492
Gaborit, B., Ancel, P., Abdullah, A., Maurice, F., Abdesselam, I., Calen, A., Soghomonian, A., Houssays, M., Varlet, I., Eisinger, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14140569
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010696
Li, H., Lip, G. Y. H., Feng, Q., Fei, Y., Tse, Y.-K., Wu, M.-Z., Ren, Q.-W., Tse, H., Cheung, B.-M. Y., & Yiu, K.-H. (2021) · Figshare · doi:10.6084/m9.figshare.14559209
Lyu, Y. S., Oh, S. K., Kim, J. H., Kim, S. Y., & Jeong, M. H. (2024) · Figshare · doi:10.6084/m9.figshare.26605981
Yu, Y.-W., Zhao, X.-M., Wang, Y.-H., Zhou, Q., Huang, Y., Zhai, M., & Zhang, J. (2021) · Figshare · doi:10.6084/m9.figshare.13642061
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010687
Carluccio, E., Biagioli, P., Reboldi, G., Mengoni, A., Lauciello, R., Zuchi, C., D’Addario, S., Bardelli, G., & Ambrosio, G. (2024) · Figshare · doi:10.6084/m9.figshare.26614570
Thirumathyam, R., Richter, E. A., van Hall, G., Holst, J. J., Fenger, M., Gøtze, J. P., Dixen, U., Vejlstrup, N., Madsbad, S., Madsen, P. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26664142
Li, J., Yu, Y., Sun, Y., Yu, B., Tan, X., Wang, B., Lu, Y., & Wang, N. (2023) · Figshare · doi:10.6084/m9.figshare.24329832
Giugliano, D., Longo, M., Scappaticcio, L., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Figshare · doi:10.6084/m9.figshare.17254158
Yu, Y.-W., Zhao, X.-M., Wang, Y.-H., Zhou, Q., Huang, Y., Zhai, M., & Zhang, J. (2021) · Figshare · doi:10.6084/m9.figshare.13642058
Yu, Y.-W., Zhao, X.-M., Wang, Y.-H., Zhou, Q., Huang, Y., Zhai, M., & Zhang, J. (2021) · Figshare · doi:10.6084/m9.figshare.13642052
Canet Suquillo, F. G. (2023) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia)
Treatment of type 2 diabetes through oral delivery of insulin : best outcomes are to come yet?
Ribeiro, J. R. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Hasse, M. (2024) · Qucosa (Saxon State and University Library Dresden)
Rynkiewicz, A. K. K. I. K., Sadowski, J. K. K. I. K., Nowek, P. K. K. I. K., & Cygański, P. K. K. I. K. (2018) · Via Medica Journals
Modern therapeutic approaches to diabetic nephropathy
Τσέλιου, Κ. Σ., & Τσέλιου, Κ. Σ. (2024) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.39686
Positron emission tomography imaging of disease activity in atherosclerosis
Virta, J. (2024) · UTUPub (University of Turku)
Kotha, S. (2024) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Omar, M., Jensen, J., Ali, M., Frederiksen, P. H., Kistorp, C., Videbæk, L. E., Poulsen, M. I., Tuxen, C., Borlaug, B. A., Möller, S., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvaf031 · Cited by 1
SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy
Sheashaa, H., Ibrahim, R., Pham, H. N., Awad, K., Scalia, I. G., Farina, J., Tamarappoo, B. K., Holloway, C. J., Arsanjani, R., & Ayoub, C. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100722
“Mechanisms underlying the benefits of SGLT2i include reduction of preload through osmotic diuresis and natriuresis, improved afterload via endothelial vasodilation, and enhanced cardiac efficiency with optimized myocardial metabolism [9,10].”
Ye, N., & Cheng, H. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s540082
Shanmugam, Y., kannuchamy, M., & Ravikumar, L. (2026) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2026.100764
Chen, X.-Y., Zhang, Y., Wang, X.-X., Hao, L.-Y., Xue, M., & Xiao, W. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02101-7
“Multiple cardiovascular outcome trials have confirmed that SGLT2i can mildly elevate circulating β-OHB levels, improving myocardial energy efficiency through the “thrifty substrate hypothesis” [14–16].”
Guo, Q., Wei, M., Shang, S., Lv, H., Tuerhong, Z., Xu, Y., Gu, X., Lu, Y., & Tang, B. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02886-6
Cao, X., Li, X., Yu, H., Liu, Z., Zhou, F. L., Chen, Z., Shao, W., Zhao, Y., Yang, X., & Li, P. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113166
Agarwal, V., Das, S., Choudhury, A. K., Meher, D., Sahoo, D., Sahu, S. K., Priyadarshini, S., Agarwal, S. J., Prusty, B., Das, B. K., et al. (2026) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_635_25 · Cited by 1
“[28] Similar observations have been reported in PCOS and insulin‑resistant states treated with metformin, where withdrawal of therapy often leads to recurrence of metabolic and endocrine abnormalities.”
SGLT2 independent effects of the SGLT2 inhibitor empagliflozin:Focus on the heart
Chen, S. (2024) · UvA-DARE (University of Amsterdam)
SGLT2 Inhibition Induces Kidney Enlargement in Experimental Rats
Wu, X. (2021) · TSpace (University of Toronto)
Siriwattanasit, N., & Satirapoj, B. (2026) · Journal of the Nephrology Society of Thailand · doi:10.63555/jnst.2026.284182
DAS, P., Pal, M., AKRAM, W., & Das, B. P. (2026) · International Journal of Current Pharmaceutical Research · doi:10.22159/ijcpr.2026v18i2.8085
Sodium glucose transporter 2 inhibitors for heart failure
Usuda, D., Furukawa, D., Imaizumi, R., Ono, R., Kaneoka, Y., Nakajima, E., Kato, M., Sugawara, Y., Shimizu, R., Inami, T., et al. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i3.118227
Liu, Q., Ning, J., Chen, Z., Wang, Z., Qian, H., Zhang, D., & Zhou, X. E. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1742232
“Given their pleiotropic metabolic effects (Cowie and Fisher, 2020; Ferrannini et al., 2016), including potential impacts on circulating metabolites and ion exchangers like the Na+/H+ exchanger (NHE) (Abdulrahman et al., 2022; Baartscheer et al., 2017; Dasari et al., 2023), we hypothesize that…”
Induction de la sénescence endothéliale par le high glucose : rôle des transporteurs SGLT1 et SGLT2
Khemais‐Benkhiat, S. (2017) · theses.fr (ABES) · doi:10.70675/6d5b1ff7z81edz4455z84caz94bf7dc9b298
Suciu, I. M., Muntean, C., Gaiţă, L., Mateoc-Sirb, T., Vlad, D. C., Timar, B., & Gaiță, D. I. (2026) · Biomedicines · doi:10.3390/biomedicines14040842
“…reduced preload and afterload through osmotic diuresis and natriuresis [60]; (c) anti-inflammatory effects, mediated through suppression of the NLRP3 inflammasome pathway [61]; and (d) metabolic reprogramming favoring ketone body utilization as a more efficient myocardial fuel substrate [62].”
The significant role of gliflozins in the treatment of type 2 diabetes mellitus
Kolesárová, M., Bučková, M., Marcinčáková, D., Mačeková, Z., & Takáč, P. (2026) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.072
Padda, B., Kelleher, J. T., Muroke, V., Sridhar, V. S., Tremblay‐Gravel, M., Tardif, J., & Boulet, J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1809193
“Furthermore, a “thrifty substrate” hypothesis proposed by Ferrannini et al. has been widely cited as a potential cardiorenal protective mechanism of SGLTi (45).”
Finerenone and Empagliflozin in Type 2 Diabetes
Abdullah, M., Khalid, N., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001308
Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study
Chmiela, T., Dulski, J., Heckman, M. G., Fang, Z. J., Wszołek, Z. K., & Wilson, J. R. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1825229 · Cited by 1
“For instance, SGLT2 inhibition shifts systemic metabolism toward ketone body utilization ( β -hydroxybutyrate), which serves as an efficient, neuroprotective energy substrate independent of body mass changes (28, 37).”
Su, Q., Huang, W., Hu, C., Huang, Y., Mo, L.-E., Wu, Q., & Huang, Y. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.048427
“13,14 However, the precise relationship between baseline ketone body metabolism and SGLT2 inhibitor efficacy remains incompletely characterized.”
Cersósimo, E., & DeFronzo, R. A. (2026) · Kidney International · doi:10.1016/j.kint.2026.02.045
Abushwereb, H. S., Roaeid, R. B. M., & Mukassabi, M. I. (2026) · Journal of diabetology research. · doi:10.52338/jodr.2026.5810
Khanna, V., Batra, A., Kumar, A., Juneja, S., & Pandeya, A. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00306-3
“Furthermore, a shift toward ketone body utilization optimizes myocardial energy efficiency in the bioenergetically compromised diabetic heart [24].”
Metabolic regulation and heart failure
Du, T., & Zhanpeng, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34186-1.00022-0
Alshammeri, T., Sayed, I. E., & Abdelazim, D. (2026) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2026.07.003
Tian, X., Ma, X., Song, E., Li, X., Fu, W., He, H., Gao, Z., & Gao, B. (2026) · Translational research · doi:10.1016/j.trsl.2026.07.008
Cardioprotective properties of empagliflozin and other SGLT2 inhibitors
Zelniker, T. A., & Braunwald, E. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01325-4
Irisin upregulation as a contributory mechanism for the therapeutic benefits of SGLT-2 inhibitors
Noto, N. M., Martin, K., Fidelia, S., Parmar, M. S., Cubeddu, L. X., Gurusamy, N., & Speth, R. C. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109090
Felici, F. D., & D'Agnese, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10197673/v1
Shin, S. M., Lee, J. Y., Kim, Y.-E., Kim, J. A., Kim, K. J., Kim, K. J., Kim, H. Y., Kim, S. G., & Kim, N. H. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113476
Estopiñan, L. F., Ros, M., Ramos, A., de la Vega, C. P., & Joaquín, C. (2026) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2026.501878
Rüggeberg, A., & Podesta, A. M. C. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.06.030
The Effect of SGLT2 Inhibitors on Antianginal Therapy Dynamics in Diabetic CABG Patients
Çakan, F., Çoner, A., Akbay, E., Öncel, C. R., & Köseoğlu, C. (2026) · Acta Medica Alanya · doi:10.30565/medalanya.1955146
Zhang, X., Mao, Y., Wu, J., Deng, X., Wang, H., & Kang, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1903580
“…systemic glucose regulation, endocrine interactions, or the complex pathological features of diabetic sarcopenia, the current data should be interpreted as cell-based evidence of local anti-in fl ammatory activity rather than direct proof of therapeutic ef fi cacy in diabetic sarcopenia (16 – 30).”
Krukowski, P., Gąsior, Z., Grabowska, M., Stermach, M., Maciejowski, M., Zdaniewicz, M., Lecyk, Z., Leszek, A., Ćwiek, K., & Przedborska, A. (2026) · Archiv Euromedica · doi:10.35630/2026/16/iss.4.10
Zou, Y., Ahmad, A., Zhang, S., Wang, Y., Ren, Q., Wang, H., Li, L., Wang, X., & Fan, F. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261479969
“33,34 The failing RV, which is often energy-starved, may particularly benefit from this shift, leading to improved contractility and resilience.”
Ahad, A., & Hullon, D. (2026) · Cardiovascular Toxicology · doi:10.1007/s12012-026-10187-8
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals
Ferrannini, E. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_824
Self-citationYao, Y., Gu, Z., Hu, J., Zhu, W., & Lin, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108466
SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications
Zheng, X.-T., Xie, H.-Y., Wang, X.-H., Zhao, Y., Yang, J.-Y., Liu, Y.-X., Yuan, X.-L., Tang, H.-F., Jiang, Z., & Hu, H.-J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00604-3
“The “thrifty substrate” hypothesis proposes that the cardiac effects of SGLT2 inhibition may partly reflect a shift towards ketone body utilisation [37].”
Implications of the outcome of EMPA-REG outcome on type 2 diabetes mellitus management
Gogoi, M., Saslu, K. N., Kumar, P., Kalita, P. P., & Chetan, P. (2022) · Medico Research Chronicles
Nadine Ahmed Raafat, R. H. E.-A. (2024) · Cuestiones de Fisioterapia · doi:10.48047/60np5h83
Kim, B., Kim, J., Kim, G., & Kim, K. (2026) · Pharmaceuticals · doi:10.3390/ph19101572
“Independently of HTD1801, GLP-1 receptor agonists and SGLT2 inhibitors provide important cardiovascular and renal benefits, including reductions in major adverse cardiovascular events, cardiovascular death, and progression of chronic kidney disease [7,8].”
Beyond Glycemic Control: SGLT2 Inhibitors as Modulators of Post-Infarction Myocardial Remodeling
Shaimaa Wageeh, T. A. N. (2024) · Cuestiones de Fisioterapia · doi:10.48047/vkm71r84
Metadata
- Authors
- Ferrannini, E., Mark, M., & Mayoux, E.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-11
- Volume
- 39
- Issue
- 7
- Pages
- 1108-1114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2412800896
- Cited by
- 975
- References
- 77
- Citations by year
- 2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
- FWCI
- 125.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.